^
4ms
Trial termination • Combination therapy • Metastases
|
CD4 (CD4 Molecule)
|
Keytruda (pembrolizumab) • MK-2118
almost2years
Trial completion • Combination therapy • Metastases
|
CD4 (CD4 Molecule)
|
Keytruda (pembrolizumab) • MK-2118
almost2years
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
CD4 (CD4 Molecule)
|
Keytruda (pembrolizumab) • MK-2118
over2years
Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001) (clinicaltrials.gov)
P1, N=160, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting | Trial completion date: Oct 2022 --> May 2023 | Trial primary completion date: Oct 2022 --> May 2023
Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy
|
CD4 (CD4 Molecule)
|
Keytruda (pembrolizumab) • MK-2118
over2years
Trial completion date • Trial primary completion date • Combination therapy
|
CD4 (CD4 Molecule)
|
Keytruda (pembrolizumab) • MK-2118